ArticleEuropean journal of nuclear medicine and molecular imaging2013
Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Article in European journal of nuclear medicine and molecular imaging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma.European journal of nuclear medicine and molecular imaging · 2020Guideline
- Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.Journal of neuro-oncology · 2023Article
- Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors.Cancers · 2022Review
- Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives.Endocrine · 2022Review
- Clinical relevance ofRadiology and oncology · 2020Article
- Article
- Current Status of Theranostics in Jordan.Nuclear medicine and molecular imaging · 2019Review
- Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy.The British journal of radiology · 2018Review
- Bortezomib sensitizes thyroid cancer to BRAF inhibitorEndocrine-related cancer · 2018Article
- Somatostatin receptor PET ligands - the next generation for clinical practice.American journal of nuclear medicine and molecular imaging · 2018Review
- Patient-specific dosimetry ofEJNMMI physics · 2017Article
- Guideline for PET/CT imaging of neuroendocrine neoplasms withEuropean journal of nuclear medicine and molecular imaging · 2017Article
- Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.European journal of nuclear medicine and molecular imaging · 2016Review
- Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment?European journal of nuclear medicine and molecular imaging · 2015Article
- Efficient Identification of Murine M2 Macrophage Peptide Targeting Ligands by Phage Display and Next-Generation Sequencing.Bioconjugate chemistry · 2015Article
- Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.Scandinavian journal of gastroenterology · 2015Review
- Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer.World journal of gastroenterology · 2014Review
- Twins in spirit part II: DOTATATE and high-affinity DOTATATE--the clinical experience.European journal of nuclear medicine and molecular imaging · 2014Article
- Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.Clinical and translational imaging · 2014Review
- PET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs Tumors.TheScientificWorldJournal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to evaluate the impact of (68)Ga-labelled DOTA(0)-lanreotide ((68)Ga-DOTA-LAN) on the diagnostic assessment of neuroendocrine tumour (NET) patients with low to moderate uptake on planar somatostatin receptor (SSTR) scintigraphy or (68)Ga-labelled DOTA(0),Tyr(3)-octreotide ((68)Ga-DOTA-TOC) positron emission tomography (PET).
methodsFifty-three patients with histologically confirmed NET and clinical signs of progressive disease, who had not qualified for peptide receptor radionuclide therapy (PRRT) on planar SSTR scintigraphy or (68)Ga-DOTA-TOC PET (n = 38) due to lack of tracer uptake, underwent (68)Ga-DOTA-LAN PET to evaluate a treatment option with (90)Y-labelled lanreotide according to the MAURITIUS trial. The included patients received 150 ± 30 MBq of each radiopharmaceutical intravenously. PET scans were acquired 60-90 min after intravenous bolus injection. Image results from both PET scans were compared head to head, focusing on the intensity of tracer uptake in terms of treatment decision. CT was used for morphologic correlation of tumour lesions. To further evaluate the binding affinities of each tracer, quantitative and qualitative values were calculated for target lesions.
results(68)Ga-DOTA-LAN and (68)Ga-DOTA-TOC both showed equivalent findings in 24/38 patients when fused PET/CT images were interpreted. The sensitivity, specificity and accuracy of (68)Ga-DOTA-LAN in comparison to CT were 0.63, 0.5 and 0.62 (n = 53; p < 0.0001) and for (68)Ga-DOTA-TOC in comparison to CT 0.78, 0.5 and 0.76 (n = 38; p < 0.013), respectively. (68)Ga-DOTA-TOC showed a significantly higher maximum standardized uptake value (SUV(max)) regarding the primary tumour in 25 patients (p < 0.003) and regarding the liver in 30 patients (p < 0.009) compared to (68)Ga-DOTA-LAN. Corresponding values of both PET scans for tumour and liver did not show any significant correlation. (68)Ga-DOTA-TOC revealed more tumour sites than (68)Ga-DOTA-LAN (106 vs 53). The tumour to background ratios for tumour and liver calculated from SUV(max) measurements were significantly higher for (68)Ga-DOTA-TOC than (68)Ga-DOTA-LAN (p < 0.02).
conclusion(68)Ga-DOTA-TOC PET imaging is an established imaging procedure for accurate staging of NET patients. (68)Ga-DOTA-LAN should only be considered as a PET tracer of second choice in patients with no pathologic tracer uptake on (68)Ga-DOTA-TOC PET. In these patients, (68)Ga-DOTA-LAN PET can provide valuable information when evaluating PRRT as the treatment option, as a broader spectrum of human SSTR subtypes can be detected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.